These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Riether C; Pabst T; Höpner S; Bacher U; Hinterbrandner M; Banz Y; Müller R; Manz MG; Gharib WH; Francisco D; Bruggmann R; van Rompaey L; Moshir M; Delahaye T; Gandini D; Erzeel E; Hultberg A; Fung S; de Haard H; Leupin N; Ochsenbein AF Nat Med; 2020 Sep; 26(9):1459-1467. PubMed ID: 32601337 [TBL] [Abstract][Full Text] [Related]
85. CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia. Iwasaki M; Liedtke M; Gentles AJ; Cleary ML Cell Stem Cell; 2015 Oct; 17(4):412-21. PubMed ID: 26387756 [TBL] [Abstract][Full Text] [Related]
86. Cancer Stem Cells in the Development of Novel Therapeutics for Refractory Pediatric Leukemia. Brennan L; Narendran A Stem Cells Dev; 2019 Oct; 28(19):1277-1287. PubMed ID: 31364487 [TBL] [Abstract][Full Text] [Related]
87. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia. Laverdière I; Boileau M; Neumann AL; Frison H; Mitchell A; Ng SWK; Wang JCY; Minden MD; Eppert K Blood Cancer J; 2018 Jun; 8(6):52. PubMed ID: 29921955 [TBL] [Abstract][Full Text] [Related]
89. The potential of targeting malignant stem cells as a treatment for leukemia. Jordan CT Future Oncol; 2005 Apr; 1(2):205-7. PubMed ID: 16555992 [TBL] [Abstract][Full Text] [Related]
90. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Jin L; Hope KJ; Zhai Q; Smadja-Joffe F; Dick JE Nat Med; 2006 Oct; 12(10):1167-74. PubMed ID: 16998484 [TBL] [Abstract][Full Text] [Related]
91. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Jin B; Wang C; Li J; Du X; Ding K; Pan J Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973 [TBL] [Abstract][Full Text] [Related]
92. Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6. Zhou M; Zhang X; Liu C; Nie D; Li S; Lai P; Jin Y Oncogene; 2021 May; 40(20):3564-3577. PubMed ID: 33931742 [TBL] [Abstract][Full Text] [Related]
93. The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38- leukemic progenitors. Costello R; Mallet F; Chambost H; Sainty D; Arnoulet C; Gastaut JA; Olive D Leukemia; 1999 Oct; 13(10):1513-8. PubMed ID: 10516751 [TBL] [Abstract][Full Text] [Related]
94. Low-Dose Triptolide Enhanced Activity of Idarubicin Against Acute Myeloid Leukemia Stem-like Cells Via Inhibiting DNA Damage Repair Response. Shi P; Zha J; Feng J; Jiang Z; Zhao H; Deng M; Liao N; Li P; Jiang Y; Song H; Xu B Stem Cell Rev Rep; 2021 Apr; 17(2):616-627. PubMed ID: 33078278 [TBL] [Abstract][Full Text] [Related]
96. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia. Ilhan O; Narli Ozdemir Z; Dalva K; Arslan A; Okay Ozgeyik M; Ipek S; Saydam G; Haznedaroglu IC Int J Lab Hematol; 2021 Oct; 43(5):1110-1116. PubMed ID: 33834631 [TBL] [Abstract][Full Text] [Related]
97. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms. Tan M; Zhang Q; Yuan X; Chen Y; Wu Y J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525 [TBL] [Abstract][Full Text] [Related]
98. Multi-parameter fluorescence-activated cell sorting and analysis of stem and progenitor cells in myeloid malignancies. Will B; Steidl U Best Pract Res Clin Haematol; 2010 Sep; 23(3):391-401. PubMed ID: 21112038 [TBL] [Abstract][Full Text] [Related]
99. Survival regulation of leukemia stem cells. Hu Y; Li S Cell Mol Life Sci; 2016 Mar; 73(5):1039-50. PubMed ID: 26686687 [TBL] [Abstract][Full Text] [Related]
100. The malignant transformation potential of the oncogene STYK1/NOK at early lymphocyte development in transgenic mice. Yang Y; Liu L; Tucker HO Biochem Biophys Rep; 2024 Jul; 38():101709. PubMed ID: 38638675 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]